news
AI holds promise to accelerate drug repurposing for COVID-19
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
List view / Grid view
Screening
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
news
Machine learning reveals potential COVID-19 therapeutic compounds
A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.
news
Raman technique developed for high-throughput discovery of enzymes
A flow mode Raman-activated cell sorter called FlowRACS has been created by researchers for high-throughput discovery of enzymes and their cell factories.
news
New chemical screening method could reveal molecular glue degraders
A phenotypic chemical screen has been developed that could be used to discover molecular glue degraders which induce the degradation of target proteins.
news
Screening process may enhance mAb drug development, say scientists
Screening potential monoclonal antibody (mAb) drugs on their colloidal stability could eliminate mAbs that do not respond efficiently in solution.
news
Functioning lung cell assay for modelling COVID-19 infections developed
A UK company has announced that their lung epithelium model can successfully be used to test potential treatments for COVID-19.
news
SRI-37330 revealed as drug candidate for treatment of diabetes
A study has shown that SRI-37330 is successful at improving the characteristics of diabetes in human pancreatic islets and animal models.
news
High-throughput screening reveals 21 drugs with activity against COVID-19
After screening 12,000 existing drugs, scientists have identified 21 which prevent the replication of SARS-CoV-2 in concentrations safe for patients.
news
Imaging and machine learning system created to discover tuberculosis drugs
Researchers have developed MorphEUS, a technology to identify new drugs that combat M. tuberculosis by revealing how compounds destroy the bacteria.
whitepaper
Whitepaper: Big data and connected tools
As more of the small devices in the lab become connected, more laboratory workflows will be observable, and variability will be better understood.
whitepaper
Case Study: Lab digitalisation and interoperability
Learn how one lab is saving time, improving traceability, and standardising protocols by using connected tools and recording all workflows digitally.
whitepaper
Interview: Stefan Braam, CEO & Founder of Ncardia
Mass production with iPSCs: how Ncardia has pushed the boundaries with high-throughput iPSC research.
whitepaper
Whitepaper: Neuroinflammation study
Neuroinflammation study by combining human iPSC-derived astrocytes and HTRF.
whitepaper
Brochure: Particle analysis re-imagined with the Aura™
Get reproducible and quantitative count, size, morphology and particle ID in one system with the Aura™.
whitepaper
Whitepaper: iPSC manufacturing for drug discovery
Controlled manufacturing of hiPSC-derived cardiomyocytes in stirred-tank bioreactors enabling high-throughput phenotypic screening.
